Trevena, Inc. · OTC:TRVN

Trevena — Investor Presentation (April 2019)

43 slides from Trevena's investor presentation, April 2019

  1. Slide 1: April 2019

    April 2019 1

  2. Slide 2: Forward looking statements and other important cautions

    Forward looking statements and other important cautions To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc., they are forward-looking statements reflecting management’s current beliefs and expectations. Forward-looking stateme

  3. Slide 3: Management and board of directors

    Management and board of directors Senior management Board of directors Carrie L. Bourdow Leon O. Moulder, Jr. President & Chief Executive Officer Chairman of the Board Mark A. Demitrack, M.D. Michael R. Dougherty SVP, Chief Medical Officer Director Robert T. Yoder Carrie Bourdow SVP, Chief Business

  4. Slide 4: Trevena corporate snapshot (Nasdaq: TRVN)

    Trevena corporate snapshot (Nasdaq: TRVN) • Publicly traded biopharmaceutical company focused on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system (CNS) • $61.5M cash and marketable securities as of 12/31/2018; f

  5. Slide 5: We are developing innovative therapies for patients impacted by CNS conditions

    We are developing innovative therapies for patients impacted by CNS conditions Preclinical Ph1 Ph2 Ph3 NDA OLICERIDINE Management of moderate to severe acute pain G protein-selective agonist at the mu-opioid receptor Path forward for NDA resubmission TRV250 Acute treatment of migraine G protein-sele

  6. Slide 6: OLICERIDINE

    OLICERIDINE G protein-selective agonist at the mu-opioid receptor Management of moderate to severe acute pain • CRL received on Nov 2, 2018 • Type A meeting minutes received in Jan 2019, provided clarity on path forward for NDA resubmission • Awaiting FDA feedback on healthy volunteer study protocol

  7. Slide 7: Path forward to NDA resubmission is focused and addressable

    Path forward to NDA resubmission is focused and addressable Clinical item Healthy volunteer study protocol for collecting requested QT interval data has been submitted to FDA for review • Only additional clinical data requested by FDA in CRL • Includes placebo- and positive-control arms • Total samp

  8. Slide 8: Hospital pain management practice depends on IV opioids as part of multimodal analgesia

    Hospital pain management practice depends on IV opioids as part of multimodal analgesia ~45M hospital patients treated annually with IV opioids Opioid-predominant regimens Multimodal pain • More severe pain • Prolonged pain management • Visceral/deep pain IV opioids Opioid-sparing regimens Non-opioi

  9. Slide 9: Opioid-related adverse events (ORAEs) place a heavy burden on hospital resources

    Opioid-related adverse events (ORAEs) place a heavy burden on hospital resources • Inpatients with ORAEs have a 3.4x risk of mortality1 ~50% higher costs • Opioid-induced nausea/vomiting can add hospital costs of $5,613 per hospital stay for on average per patient2 postsurgical inpatients • One crit

  10. Slide 10: Oliceridine is designed to improve IV opioid pharmacology through a new mechanism of action

    Oliceridine is designed to improve IV opioid pharmacology through a new mechanism of action First G-protein selective µ-agonist Oliceridine Innovative µ-opioid receptor mechanism of action Cell surface Head to head G Cell interior clinical data vs. morphine protein β-arrestin Clinical data in at-ris

  11. Slide 11: Consistent efficacy and demonstrated safety and tolerability throughout oliceridine program

    Consistent efficacy and demonstrated safety and tolerability throughout oliceridine program Preclinical data1,2 ● New chemotype, first-in-class G protein-selective mu agonist ● 4-10x improvement in respiratory depression & constipation vs. morphine Phase 1b experimental medicine data3 ● More analges

  12. Slide 12: All three oliceridine regimens met primary efficacy endpoint vs. placebo in both Phase 3 APOLLO trials

    All three oliceridine regimens met primary efficacy endpoint vs. placebo in both Phase 3 APOLLO trials Mean baseline pain = 6.7 Mean baseline pain = 7.3 Primary endpoint P = 0.0004 • Treatment responder if all 4 P < 0.0001 # P < 0.0001 criteria met: # P = 0.029 – ≥ 30% improvement in SPID – Without

  13. Slide 13: Phase 3 data: Respiratory safety burden

    Phase 3 data: Respiratory safety burden oliceridine vs. IV morphine Respiratory safety burden: An integrated clinical assessment of respiratory status Mean O2 saturation at Mean O2 saturation at time of event = 84% time of event = 88% 1.0 (vs. 97% without event) (vs. 97% without event) 1.0 Respirato

  14. Slide 14: Phase 3 data: Gastrointestinal tolerability

    Phase 3 data: Gastrointestinal tolerability oliceridine vs. IV morphine Vomiting Antiemetic use Vomiting Antiemetic use 60 80 60 80 patients patients of patients Percentage of patients ofpatients Percentage ofofpatients 60 60 (%) 40 40 antiemetic use * Percentage of Percentage Percentage Percentage

  15. Slide 15: Phase 3 oliceridine safety and tolerability highlighted by pattern of dosing interruptions

    Phase 3 oliceridine safety and tolerability highlighted by pattern of dosing interruptions Dosing interruptions for safety/tolerability were fewer and shorter for 0.35 mg oliceridine than morphine (p<0.05 for frequency in APOLLO 1, duration in APOLLO 2) hours Gray: on-demand doses 15 Red: temporary

  16. Slide 16: ATHENA Phase 3 open label safety study: Broad range of patients and surgeries

    ATHENA Phase 3 open label safety study: Broad range of patients and surgeries • Trial modeled real-world use: usual patient care Medical 11 except oliceridine instead of standard IV opioid Cardiothoracic 18 Bariatric surgery 18 • Administered as part of multimodal analgesia: Emergency 33 – Titration

  17. Slide 17: Clinical trial data for oliceridine supports a compelling profile for complex patients

    Clinical trial data for oliceridine supports a compelling profile for complex patients who require an IV opioid IV opioid-level efficacy No dosage adjustment for Rapid onset elderly or renally impaired oliceridine Favorable safety No known active & tolerability metabolites profile Oliceridine is an

  18. Slide 18: Significant unmet need in large addressable market

    Significant unmet need in large addressable market 45+ million IV opioid-treated US hospital patients annually1 Unmet need: Unmet need: opioid efficacy 15 million 30 million reduce ORAEs to with improved Inpatients Outpatients speed patient safety/tolerability discharge ~30 million days of therapy R

  19. Slide 19: Hospital trends align with key drivers for uptake of oliceridine

    Hospital trends align with key drivers for uptake of oliceridine Current trends that may impact key elements of oliceridine uptake… Hospitals Patient care Surgical practice • Consolidations: IDNs, ACOs • Hospitalized patients more complex • Increase in painful surgeries expected to grow, e.g. bariat

  20. Slide 20: Initial target for oliceridine: complex patients and priority procedures

    Initial target for oliceridine: complex patients and priority procedures Complex patients Severe pain patients • Obese • Orthopedic • Renal impairment • Colorectal • Elderly • Cardiothoracic • Medical co-morbidities Target population for oliceridine 7M to 9M hospital patients 20

  21. Slide 21: We have a targeted hospital formulary pull through plan

    We have a targeted hospital formulary pull through plan Hospital decision makers in formulary review process 1 Physician 2 Pharmacy department 3 P&T committee Submits request Conducts formal Reviews assessment and for drug review product assessment votes to revise formulary *Physician champion is ke

  22. Slide 22: Robust data package will support formulary decision-making process

    Robust data package will support formulary decision-making process Majority of formulary stakeholders believe that oliceridine pivotal data is clinically meaningful1: Key Endpoint2 Pharmacy (n=160) Physicians (n=40) Reduction in Respiratory Safety Events 74% 90% Reduction in Vomiting 70% 87% Phase 3

  23. Slide 23: Robust data set exists to support future commercialization and hospital formulary committee uptake

    Robust data set exists to support future commercialization and hospital formulary committee uptake • 1st in class novel chemical entity • Indication: Management of moderate to severe acute pain requiring IV opioid Health Care • Fast onset of action Practitioners (HCPs) • No known active metabolites

  24. Slide 24: Targeted commercial execution will drive early adoption and rapid uptake of oliceridine

    Targeted commercial execution will drive early adoption and rapid uptake of oliceridine Factors for selecting “early adopter”1 hospitals 1,200 hospitals accounting for • High volume of severe and painful procedures ~70% of total IV opioid vol. • High volume of IV opioid use • Rapid adoption of launc

  25. Slide 25: Market research with formulary stakeholders has identified a launch price range for oliceridine

    Market research with formulary stakeholders has identified a launch price range for oliceridine $60 Avg.* price per day of oliceridine $100 • Physicians believe oliceridine provides clinical value over conventional IV opioids • Majority of formularies would include oliceridine with expected patient/

  26. Slide 26: Focused hospital launch plan for oliceridine

    Focused hospital launch plan for oliceridine Initial focus will be on addressing significant unmet need in a large addressable market: Patients Physician Specialties Hospitals ~45M patients in the US ~12 specialties across settings ~5,800 hospitals in the US ~9M patients ~4 specialties ~600 hospital

  27. Slide 27: We are developing innovative therapies for patients impacted by CNS conditions

    We are developing innovative therapies for patients impacted by CNS conditions Preclinical Ph1 Ph2 Ph3 NDA OLICERIDINE Management of moderate to severe acute pain G protein-selective agonist at the mu-opioid receptor Path forward for NDA resubmission TRV250 Acute treatment of migraine G protein-sele

  28. Slide 28: TRV250

    TRV250 G protein-selective agonist at the delta receptor Acute treatment of migraine • Delta receptor holds potential for broad application across number of CNS conditions • Migraine offers opportunity to test mechanism of effect using validated and cost-effective biomarker model • Proof of mechanis

  29. Slide 29: New MOA at delta receptor: Untapped potential in CNS space

    New MOA at delta receptor: Untapped potential in CNS space • Play important role in regulation of mood, pain, Delta receptors have anxiety, and movement disorders unique distribution throughout the brain • Potential for broad application across number of CNS indications (% reversal of NTG-induced hy

  30. Slide 30: Initial approach: Acute treatment of migraine

    Initial approach: Acute treatment of migraine 610M migraines Key opportunity: treated annually ~25% of patients don’t benefit in US1 from/can’t tolerate triptans Next step: Proof of mechanism study • Focused approach to determining target engagement via a validated biomarker model • Not a large, dia

  31. Slide 31: TRV734

    TRV734 G protein-selective agonist at the mu-opioid receptor Oral management of opioid use disorder • Two successful Phase 1 studies that support advancing to Phase 2 • Ongoing collaboration with National Institute on Drug Abuse (NIDA); efficacy demonstrated in animal model of opioid relapse • Clini

  32. Slide 32: Selective agonism at mu-opioid receptor: A new approach for managing opioid use disorder

    Selective agonism at mu-opioid receptor: A new approach for managing opioid use disorder Nonclinical and Phase 1 data support advancing to Phase 2 studies • Strong nonclinical evidence of biased agonism: less constipation compared to conventional opioids, no evidence of opioid-induced hyperalgesia •

  33. Slide 33: TRV045

    TRV045 Novel S1P receptor modulator Non-opioid management of chronic pain • Engages S1P receptor without lymphocyte trafficking activity • Opportunity to leverage unique intrinsic properties of S1P target • Lead candidate has been identified, transition to pre-IND underway 33 TRV045 is an investigat

  34. Slide 34: Leveraging intrinsic benefits of S1P target

    Leveraging intrinsic benefits of S1P target S1P receptors • Validated target for T cell mediated diseases – Existing programs focus on inflammatory CNS diseases, e.g. MS, UC, Crohn’s • Lymphopenia drives therapeutic benefit but increases immune suppression risks TRV045 • New mechanism of S1P recepto

  35. Slide 35: New opportunity for non-opioid pain relief

    New opportunity for non-opioid pain relief Veh/Veh Pac/Veh Vehicle 0.03 mg/kg Fingolimod * TRV compound TRV compound 0.1 mg/kg Ozanimod * 0.3 mg/kg * 0 50 100 150 Peripheral Lymphocyte Count 1 mg/kg * (AUC 0-24 hours, % of saline control) 00 2020 40 40 60 80 60 100 80 100 % reversal of CIPN hyperalg

  36. Slide 36: Summary

    Summary Oliceridine targets a substantial addressable market opportunity Path forward to address CRL and resubmit oliceridine NDA Comprehensive data set will be available at launch to support oliceridine Differentiated pipeline will provide potential future catalysts Experienced management team 36

  37. Slide 37: BACKUPS

    BACKUPS WéTrevena "

  38. Slide 38: Summary of most common TEAEs across all treatment regimens

    Summary of most common TEAEs across all treatment regimens Placebo Oliceridine Morphine Most common TEAEs (N=79) 0.1mg 0.35mg 0.5mg (N=76) n (%) of patients (N=76) (N=79) (N=79) Nausea 19 (24.1) 27 (35.5) 44 (55.7) 50 (63.3) 49 (64.5) Vomiting 5 (6.3) 13 (17.1) 31 (39.2) 32 (40.5) 38 (50.0) Dizzines

  39. Slide 39: Summary of most common TEAEs across all treatment regimens

    Summary of most common TEAEs across all treatment regimens Placebo Oliceridine Morphine (N=83) 0.1mg 0.35mg 0.5mg (N=82) Most common TEAEs, n (%) of patients (N=77) (N=79) (N=80) Nausea 38 (45.8) 34 (44.2) 49 (62.0) 60 (75.0) 61 (74.4) Vomiting 11 (13.3) 18 (23.4) 17 (21.5) 34 (42.5) 44 (53.7) Heada

  40. Slide 40: Onset of pain relief was rapid and consistent in Phase 2 and Phase 3 studies

    Onset of pain relief was rapid and consistent in Phase 2 and Phase 3 studies Time to meaningful pain relief Phase 2 bunionectomy study • In as-needed dosing paradigms in 50% 68% 81% 97% 56% Phase 3 trials, efficacy signal noted as 120 % reporting meaningful soon as 5 minutes after first dose pain re

  41. Slide 41: Phase 2b: nausea, vomiting, and hypoventilation were less prevalent with oliceridine than with morphine

    Phase 2b: nausea, vomiting, and hypoventilation were less prevalent with oliceridine than with morphine Phase 2b abdominoplasty study; dosing by patient controlled analgesia (PCA) Figure 4: Percent of Patients with Treatment Emergent AEs Percent of patients with opioid-related adverse events Nausea

  42. Slide 42: Oliceridine treatment associated with reduced prevalence of rescue analgesia

    Oliceridine treatment associated with reduced prevalence of rescue analgesia Placebo Oliceridine 0.1 mg Oliceridine 0.35 mg Oliceridine 0.5 mg Morphine Rescue analgesia: NSAID (etodolac) 200mg Q6h prn 42

  43. Slide 43: Respiratory safety supported by additional objective Phase 3 measurements

    Respiratory safety supported by additional objective Phase 3 measurements Oxygen desaturation Supplemental O2 Oxygen desaturation Supplemental O2 O2 saturation <90% Safety intervention O2 saturation <90% Safety intervention 25 25 30 30 Percentage of patients with O2 patients Percentage of patients P

Trevena — Investor Presentation (April 2019) on 6ix